This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

QIAGEN And Max Planck Institute For Infection Biology Collaborate To Develop Assay For Active TB Risk In Individuals With Latent Infection

HILDEN and BERLIN, Germany, January 9, 2012 /PRNewswire/ --
  • Collaboration to create molecular test assessing a person's risk for latent TB progressing to active TB, enabling early treatment and disease outbreak prevention
  • QIAGEN strengthening its leading infectious disease portfolio with development of DNA-/RNA-based test that complements QuantiFERON-TB Gold test for latent TB
  • New assay will use whole blood transcription profiling - a new diagnostic technology developed at the Max Planck Institute's Department of Immunology
  • New molecular test to be run on the QIAsymphony modular automation platform

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt: Prime Standard: QIA) and the Max Planck Institute for Infection Biology (MPIIB), Department of Immunology have announced a new collaboration to develop a molecular diagnostic test to assess the risk of an individual with latent tuberculosis (TB) developing active TB disease during their lifetime. Financial terms were not disclosed.

Approximately one-third of the world's population is estimated to be infected with Mycobacterium tuberculosis, but do not have active tuberculosis. The identification and treatment of these individuals is critical to controlling this disease since approximately 5-10% of latent TB patients are at risk for developing active TB during their lifetime, particularly those with weakened immune systems.  

As a follow-up to those who test positive for latent TB, this new test will be designed to enable early treatment before reactivation of the TB disease, when it becomes contagious and causes life-threatening respiratory illnesses and other diseases.

This new molecular reflex assay, which is based on significant research conducted at the MPIIB in Berlin, is expected to be a PCR-based test targeting multiple biomarkers. It will be designed to run on the QIAsymphony modular automation platform and to serve as a reflex test following QIAGEN's QuantiFERON-TB Gold test, the modern gold standard for detection of latent TB. The kits are not expected to be available before 2013 and will be commercialized by QIAGEN.

During TB infection, changes occur in the transcriptional profiles of immune cells circulating through blood - alterations in gene expression that reflect the body's immune response and help to distinguish between latent and active disease. The goal of QIAGEN's collaboration with the MPIIB is to format the most suitable markers from the sets of biomarkers identified by the institute into a molecular assay that can predict susceptibility or resistance to active TB disease in individuals with latent TB.

1 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.78 0.08%
FB $102.18 0.26%
GOOG $684.55 0.21%
TSLA $149.31 -0.77%
YHOO $26.86 0.37%


Chart of I:DJI
DOW 15,920.01 +259.83 1.66%
S&P 500 1,856.92 +27.84 1.52%
NASDAQ 4,322.1020 +55.2650 1.30%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs